Palantir is scheduled to report second-quarter results after the market closes Monday, with investors closely watching whether the AI software company can sustain its rapid growth and justify its premium valuation.The broader market also provided support, with Nasdaq futures rising 0.30% and S&P 500 futures gaining 0.36%.NHS Data Platform Faces Fresh ScrutinyPalantir is also facing renewed scrutiny over its NHS England data-platform contract after the U.K. health service moved to revise how it measures the platform’s impact, raising fresh questions about its effectiveness.NHS England plans to change how it evaluates the Federated Data Platform after staff raised concerns about flaws in the analysis, the Financial Times reported on Monday, citing emails.The changes will affect two key claims tied to the Palantir-built platform: that hospitals using the system delivered 110,000 additional operations and that discharge delays fell 15%.An NHS England official questioned the baseline used to assess the platform’s performance, saying the method could be distorted by seasonal patterns. Another official later told colleagues that the adjusted baseline method would appear in the next round of published figures.Effectiveness Claims Face ScrutinyFormer NHS England head of operational research and evaluation Charles Tallack said the FOI findings raise serious questions about the health service’s analytical culture. He said NHS England must ensure its published analysis follows government guidance to maintain trust in its decisions and claims.The discharge-delay data has already faced criticism. The Financial Times identified errors in an underlying dataset, while Health Foundation analysis found no noticeable improvement in discharge performance at hospitals using the patient-tracking tool.NHS England said debate, challenge and ongoing review form part of its analytical practice. It said it is making a small change to baseline statistics for NHS organizations that have used a platform product for less than 12 months.Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $183.27. Recent analyst moves include: